0 287

Cited 14 times in

Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박용은-
dc.contributor.author박준용-
dc.contributor.author박지혜-
dc.contributor.author안상훈-
dc.contributor.author윤해룡-
dc.contributor.author한광협-
dc.contributor.author박예현-
dc.date.accessioned2017-02-24T03:43:32Z-
dc.date.available2017-02-24T03:43:32Z-
dc.date.issued2016-
dc.identifier.issn1478-3223-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/146425-
dc.description.abstractBACKGROUND & AIMS: The hepatoma arterial-embolization prognostic (HAP) score predicts survival outcome in patients with hepatocellular carcinoma (HCC) treated with trans-arterial chemoembolization (TACE). We validated the HAP score in Korean subjects with HCC and investigated whether its prognostic performance is improved with additional parameters. METHODS: A total of 280 patients with HCC treated with TACE between 2003 and 2009 were included. Validation and modification of HAP score were performed based on multivariate Cox regression models. RESULTS: The median age of the study population (211 men, 69 women) was 60 years. Viral etiology of HCC accounted for 80.4% (n = 181 for hepatitis B, 44 for hepatitis C). The median overall survival (OS) was 40.5 months. On multivariate analysis, together with the original components of the HAP score (serum albumin <3.6 g/dl, total bilirubin >0.9 mg/dl, alpha-foetoprotein >400 ng/ml, and tumor size >7 cm), tumor number ≥2 was selected as an independent unfavorable prognostic factor for OS (hazard ratio 2.3; P < 0.001). Accordingly, a modified HAP-II (mHAP-II) score was established by adding tumor number ≥2. Although both HAP and mHAP-II scores discriminated the four different risk groups (log-rank test, all P < 0.001), the mHAP-II score performed significantly better than the HAP score, as per the areas under receiver-operating curves predicting OS at 3 years (0.717 vs. 0.658) and 5 years (0.728 vs. 0.645), respectively (all P < 0.05). CONCLUSIONS: Although the HAP score predicted OS for Korean subjects with HCC undergoing TACE, the addition of tumor number significantly improved the prognostic performance. The mHAP-II score can be used for accurate prognostication and selection of optimal candidates for TACE.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent100~107-
dc.languageEnglish-
dc.publisherWiley-Blackwell-
dc.relation.isPartOfLiver International-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHBiomarkers, Tumor/analysis-
dc.subject.MESHCarcinoma, Hepatocellular*/diagnosis-
dc.subject.MESHCarcinoma, Hepatocellular*/etiology-
dc.subject.MESHCarcinoma, Hepatocellular*/mortality-
dc.subject.MESHCarcinoma, Hepatocellular*/pathology-
dc.subject.MESHCarcinoma, Hepatocellular*/therapy-
dc.subject.MESHChemoembolization, Therapeutic*/adverse effects-
dc.subject.MESHChemoembolization, Therapeutic*/methods-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms*/diagnosis-
dc.subject.MESHLiver Neoplasms*/etiology-
dc.subject.MESHLiver Neoplasms*/mortality-
dc.subject.MESHLiver Neoplasms*/pathology-
dc.subject.MESHLiver Neoplasms*/therapy-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHResearch Design/standards-
dc.subject.MESHRisk Assessment/methods*-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTumor Burden-
dc.subject.MESHalpha-Fetoproteins/analysis-
dc.titleAddition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYehyun Park-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorYong Eun Park-
dc.contributor.googleauthorJi Hye Park-
dc.contributor.googleauthorYong Il Lee-
dc.contributor.googleauthorHae Ryong Yun-
dc.contributor.googleauthorKwang-Hyub Han-
dc.identifier.doi10.1111/liv.12878-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA04571-
dc.contributor.localIdA01675-
dc.contributor.localIdA04575-
dc.contributor.localIdA02226-
dc.contributor.localIdA04617-
dc.contributor.localIdA04268-
dc.contributor.localIdA01575-
dc.relation.journalcodeJ02171-
dc.identifier.pmid26013186-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/liv.12878/abstract-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordmodel-
dc.subject.keywordoverall survival-
dc.subject.keywordprediction-
dc.subject.keywordprognosis-
dc.subject.keywordtrans-arterial chemoembolization-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Yong Eun-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNamePark, Ji Hye-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameYun, Hae Ryong-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNamePark, Ye Hyun-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Yong Eun-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorPark, Ji Hye-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorYun, Hae Ryong-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorPark, Ye Hyun-
dc.citation.volume36-
dc.citation.number1-
dc.citation.startPage100-
dc.citation.endPage107-
dc.identifier.bibliographicCitationLiver International, Vol.36(1) : 100-107, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.